anidulafungin has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
| Anand, V; Bhatt, S; Das, HK; Dey, SK; Dhembla, C; Kundu, S; Rajesh, AS; Saini, M | 1 |
| Brandão, IB; Colombo, AL; de Almeida, SLR; de Andrade, TS; de Miranda Costa, MM; de Oliveira Dias, P; de Souza Jordão, RT; Francisco, EC; Meis, JF; Nobrega de Almeida, J; Pereira, FM; Santos Ferreira, F | 1 |
3 other study(ies) available for anidulafungin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |
Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2.
Topics: Anidulafungin; Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; SARS-CoV-2; Suramin | 2022 |
Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Brazil; Candida; Candidiasis; COVID-19; Critical Care; Disease Outbreaks; Disease Transmission, Infectious; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; SARS-CoV-2; Thermometers; Voriconazole | 2021 |